Flavoxate-d5 | CAS#unknown | Flavoxate internal standard

Flavoxate-d5
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465320

CAS#: unknown

Description: Flavoxate-d5 is intended for use as an internal standard for the quantification of flavoxate by GC- or LC-MS. Flavoxate is an inhibitor of L-type calcium channels and an antimuscarinic agent. It induces relaxation of potassium-precontracted isolated human urinary bladder detrusor muscle (IC50 = 2 µM) and reduces contractions induced by the acetylcholine receptor agonist carbachol (carbamoylcholine) or calcium in isolated rat detrusor strips. Microinjection of flavoxate (0.68 µg/animal) into the oral pontine reticular nucleus inhibits reflex micturition in decerebrated cats, and intravenous or intracerebroventricular administration reduces isovolumetric rhythmic bladder contractions in rats. Formulations containing flavoxate have previously been used in the treatment of frequent or urgent urination, increased nocturnal urination, bladder pain, and urinary incontinence.

Chemical Structure

Flavoxate-d5

CAS# unknown

Instruction

Theoretical Analysis

MedKoo Cat#: 465320
Name: Flavoxate-d5
CAS#: unknown
Chemical Formula: C24H20D5NO4
Exact Mass: 396.21
Molecular Weight: 396.498
Elemental Analysis: C, 72.70; H, 7.62; N, 3.53; O, 16.14

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 505	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Flavoxate-d5; Flavoxate d5;

IUPAC/Chemical Name: 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-(phenyl-d5)-4H-chromene-8-carboxylate

InChi Key: SPIUTQOUKAMGCX-ONXRJODMSA-N

InChi Code: InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3/i2D,4D,5D,9D,10D

SMILES Code: CC1=C(OC2=C(C=CC=C2C1=O)C(OCCN3CCCCC3)=O)C4=C(C([2H])=C(C([2H])=C4[2H])[2H])[2H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 396.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Loh GOK, Wong EYL, Tan YTF, Wee HC, Ng RS, Lee CY, Peh KK. Simple and rapid LC-MS/MS method for simultaneous determination of flavoxate and 3-methyl- flavone-8-carboxylic acid in human plasma: Application to a bioequivalence study. J Pharm Biomed Anal. 2021 Feb 5;194:113758. doi: 10.1016/j.jpba.2020.113758. Epub 2020 Nov 13. PMID: 33248861.

2: El-Ragehy NA, Ramadan NK, Ragab MT, El-Zeany BA. RP-HPLC Method for the Simultaneous Determination of a Quaternary Mixture of Propyphenazone, Flavoxate HCl and Two of Their Official Impurities with Dissolution Profiling of Their Tablets. J AOAC Int. 2020 Jul 1;103(4):958-965. doi: 10.1093/jaoacint/qsaa003. PMID: 33241355.

3: Zink A, Conrad J, Telugu NS, Diecke S, Heinz A, Wanker E, Priller J, Prigione A. Assessment of Ethanol-Induced Toxicity on iPSC-Derived Human Neurons Using a Novel High-Throughput Mitochondrial Neuronal Health (MNH) Assay. Front Cell Dev Biol. 2020 Nov 5;8:590540. doi: 10.3389/fcell.2020.590540. PMID: 33224955; PMCID: PMC7674658.

4: Barthold D, Marcum ZA, Gray SL, Zissimopoulos J. Alzheimer's disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs. Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1650-1658. doi: 10.1002/pds.5098. Epub 2020 Aug 27. PMID: 32852147; PMCID: PMC7825274.

5: Attimarad M, Shahzad Chohan M, Ahmed Balgoname A. Simultaneous Determination of Moxifloxacin and Flavoxate by RP-HPLC and Ecofriendly Derivative Spectrophotometry Methods in Formulations. Int J Environ Res Public Health. 2019 Apr 3;16(7):1196. doi: 10.3390/ijerph16071196. PMID: 30987126; PMCID: PMC6480697.

6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Flavoxate. 2018 Dec 3. PMID: 29999994.

7: Xue Y, Li H, Zhang Y, Han X, Zhang G, Li W, Zhang H, Lin Y, Chen P, Sun X, Liu Y, Chu L, Zhang J, Zhang M, Zhang X. Natural and synthetic flavonoids, novel blockers of the volume-regulated anion channels, inhibit endothelial cell proliferation. Pflugers Arch. 2018 Oct;470(10):1473-1483. doi: 10.1007/s00424-018-2170-8. Epub 2018 Jun 30. PMID: 29961148.

8: Nazir J, Berling M, McCrea C, Fatoye F, Bowditch S, Hakimi Z, Wagg A. Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. Pharmacoecon Open. 2017 Mar;1(1):25-36. doi: 10.1007/s41669-017-0011-x. PMID: 29442303; PMCID: PMC5689035.

9: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Flavoxate. 2018 Feb 6. PMID: 31644218.

10: Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol. 2017 Sep;72(3):389-399. doi: 10.1016/j.eururo.2017.01.037. Epub 2017 Feb 11. PMID: 28196724.

11: Sweeney P, Mutambirwa S, Van An N, Sharma JB, Vanamail P. Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis. Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3703-12. PMID: 27649675.

12: Li WH, Sun CM, Wei YJ. [Fluorescence enhancement of flavoxate hydrochloride in alkali solution and its application in pharmaceutical analysis]. Yao Xue Xue Bao. 2015 Oct;50(10):1324-9. Chinese. PMID: 26837181.

13: Tang HC, Lam WP, Zhang X, Leung PC, Yew DT, Liang W. Short-Term Flavoxate Treatment Alters Detrusor Contractility Characteristics: Renewed Interest in Clinical Use? Low Urin Tract Symptoms. 2015 Sep;7(3):149-54. doi: 10.1111/luts.12063. Epub 2014 Jun 3. PMID: 26663730.

14: Murphy RM, Bakir B, O'Brien C, Wiggs JL, Pasquale LR. Drug-induced Bilateral Secondary Angle-Closure Glaucoma: A Literature Synthesis. J Glaucoma. 2016 Feb;25(2):e99-105. doi: 10.1097/IJG.0000000000000270. PMID: 25943730.

15: Kumar S. Profile of Diseases Prevalent in a Tribal Locality in Jharkhand, India: A Family Medicine Practitioner's Perspective. J Family Med Prim Care. 2015 Jan-Mar;4(1):110-6. doi: 10.4103/2249-4863.152266. PMID: 25811000; PMCID: PMC4366980.

16: Arcaniolo D, Conquy S, Tarcan T. Flavoxate: present and future. Eur Rev Med Pharmacol Sci. 2015;19(5):719-31. PMID: 25807422.

17: Zor M, Aydur E, Dmochowski RR. Flavoxate in urogynecology: an old drug revisited. Int Urogynecol J. 2015 Jul;26(7):959-66. doi: 10.1007/s00192-014-2585-5. Epub 2014 Dec 6. PMID: 25480503.

18: Institute for Quality and Efficiency in Health Care. Mirabegron -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2014 Aug 28. Extract of Dossier Assessment No. A14-19. PMID: 26677503.

19: Zaazaa HE, Mohamed AO, Hawwam MA, Abdelkawy M. Spectrofluorimetric determination of 3-methylflavone-8-carboxylic acid, the main active metabolite of flavoxate hydrochloride in human urine. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Jan 5;134:109-13. doi: 10.1016/j.saa.2014.06.058. Epub 2014 Jun 20. PMID: 25004902.

20: Fujimoto M, Higuchi T, Hosomi K, Takada M. Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database. Int J Clin Pharmacol Ther. 2014 Sep;52(9):762-9. doi: 10.5414/CP202113. PMID: 24986095.

Your view history

Flavoxate-d5 featured